جلد 9 -
جلد 9 - : e18 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hamidia A, Kheirkhah F, Khafri S, Azadforouz S, Dadashi M, Palizban N, et al . A Comparative Study of the Efficacy of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder. CJP 2023; 9
URL: http://caspianjp.ir/article-1-203-fa.html
URL: http://caspianjp.ir/article-1-203-fa.html
A Comparative Study of the Efficacy of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder. مجله کاسپین کودکان. 1401; 9 ()
چکیده: (93 مشاهده)
Background and Objective: Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in childhood. The aim of this study was to compare the efficacy of methylphenidate (Ritalin) and atomoxetine in improving ADHD symptoms and also their side effects.
Methods: The randomized clinical trial included 60 children aged 6-14 years with ADHD who were referred to the psychiatric clinic of Yahyanejad Hospital. They were randomly divided into two groups, one of which received methylphenidate and the other atomoxetine. The patients were followed up by a psychiatrist after treatment. Improvement in symptoms was measured by examining the ADHD Rating Scale (RS) scores. The results were analyzed using an independent t-test and a value of p≤0.05 was considered significant.
Findings: The mean ADHD RS score decreased in both groups in the fourth- and eighth-week intervals after the intervention, with a statistically significant difference in the eighth week compared to pre-treatment and the fourth week for both groups (P-value=0.001). However, no statistically significant difference was observed in the mean scale score between the two groups (P-value=0.48). In the fourth week, the mean complication rate was significantly lower with atomoxetine than with methylphenidate (P-value=0.001). Even in the eighth week, no significant difference was found in the side effects of methylphenidate and atomoxetine (P-value=0.553).
Conclusion: The efficacy and tolerability of atomoxetine and methylphenidate were described as similar. However, there was no significant treatment difference between the two drugs. The frequency of side effects was similar for both drugs after eight weeks of treatment.
Methods: The randomized clinical trial included 60 children aged 6-14 years with ADHD who were referred to the psychiatric clinic of Yahyanejad Hospital. They were randomly divided into two groups, one of which received methylphenidate and the other atomoxetine. The patients were followed up by a psychiatrist after treatment. Improvement in symptoms was measured by examining the ADHD Rating Scale (RS) scores. The results were analyzed using an independent t-test and a value of p≤0.05 was considered significant.
Findings: The mean ADHD RS score decreased in both groups in the fourth- and eighth-week intervals after the intervention, with a statistically significant difference in the eighth week compared to pre-treatment and the fourth week for both groups (P-value=0.001). However, no statistically significant difference was observed in the mean scale score between the two groups (P-value=0.48). In the fourth week, the mean complication rate was significantly lower with atomoxetine than with methylphenidate (P-value=0.001). Even in the eighth week, no significant difference was found in the side effects of methylphenidate and atomoxetine (P-value=0.553).
Conclusion: The efficacy and tolerability of atomoxetine and methylphenidate were described as similar. However, there was no significant treatment difference between the two drugs. The frequency of side effects was similar for both drugs after eight weeks of treatment.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
